Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind extension study of idelalisib dose levels in previously treated chronic lymphocytic leukemia
2011-006293-72Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idelalisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Gilead Sciences. Started Mar 2012; status: completed.
02
Drugs
idelalisib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2011-006293-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006293-72.